Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
The sodium glucose co-transporter 2 (SGLT2) functions in the proximal tubule to reabsorb the bulk of filtered glucose. SGLT2 inhibitors have been developed to promote renal glucose excretion to improve glycemic control in diabetes. Regulatory guidance mandated adequately powered studies to detect in...
Saved in:
Main Authors: | Gilda M. Portalatin, Irene Hong-McAtee, Anna M. Burgner, Edward R. Gould, Tracy E. Hunley |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1521425/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comprehensive management application of sulodexide on proteinuria: 2 case reports
by: Li Zhou, et al.
Published: (2025-02-01) -
Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
by: Ioannis Bellos, et al.
Published: (2024-12-01) -
Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
by: Yu-Ling Lin, et al.
Published: (2025-01-01) -
Hepatocyte Nuclear Factor 1 Beta Mutation-associated Newborn Onset of Glomerulocystic Kidney Disease: A Case Presentation
by: Nilüfer Göknar, et al.
Published: (2021-12-01) -
La enfermedad renal crónica y la alimentación
by: Danielle Aycart, et al.
Published: (2022-08-01)